Spectrum Management Group’s Adaptive Biotechnologies ADPT Stock Holding History

Spectrum Management Group’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$0	Hold	35	–	–	﹤0.01%	238
2022 Q2	$0	Hold	35	–	–	﹤0.01%	243
2022 Q1	$0	Hold	35	–	–	﹤0.01%	317
2021 Q4	$1K	Hold	35	–	–	﹤0.01%	305
2021 Q3	$1K	Hold	35	–	–	﹤0.01%	383
2021 Q2	$1K	Hold	35	–	–	﹤0.01%	244
2021 Q1	$1K	Hold	35	–	–	﹤0.01%	224
2020 Q4	$2K	Hold	35	–	–	﹤0.01%	210
2020 Q3	$2K	Hold	35	–	–	﹤0.01%	242
2020 Q2	$2K	Buy	+35	New	+$1.28K	﹤0.01%	247

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Spectrum Management Group's ADPT Position: Q3 2022 in Review

Spectrum Management Group held its Adaptive Biotechnologies (ADPT) position steady in Q3 2022 at 35 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #238.

Spectrum Management Group first reported a position in ADPT in Q2 2020 and has held it in 10 quarters since. The position peaked at $2K in Q4 2020. 226 funds tracked by Wall St. Rank hold ADPT as of Q3 2022.

Spectrum Management Group held 35 shares of Adaptive Biotechnologies worth $0 as of Q3 2022.
Spectrum Management Group left its Adaptive Biotechnologies share count unchanged in Q3 2022.
Adaptive Biotechnologies made up ﹤0.01% of Spectrum Management Group's portfolio in Q3 2022, its #238 holding.
Spectrum Management Group first reported a position in Adaptive Biotechnologies in Q2 2020 and has held it in 10 quarters since.
Spectrum Management Group's Adaptive Biotechnologies position peaked at $2K in Q4 2020.
226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2022.

Based on Spectrum Management Group's 13F filing for Q3 2022, filed 1 Nov 2022.